Results 21 to 30 of about 4,697 (156)

Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies

Frontiers in Oncology, 2021
Bruton tyrosine kinase (BTK) is a validated target for treatment of B-cell malignancies, and oral inhibitors of BTK have emerged as a standard of care for these diseases.
Hussein A. Abbas, William G. Wierda
doaj   +1 more source

Acalabrutinib in Chronic Lymphocytic Leukemia: Pharmacology and Emerging Clinical Perspectives. [PDF]

Eur J Haematol
Acalabrutinib, a second-generation Bruton's tyrosine kinase inhibitor (BTKi), is characterized by enhanced specificity and selectivity for BTK with minimal off-target effects, offering a significant evolution in the treatment of chronic lymphocytic ...
Gaidano G, Danesi R.
europepmc   +2 more sources

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial [PDF]

, 2021
PURPOSE: Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability.
Rothbaum, Wayne, Pinilla-Ibarz, J, Seymour, John F., Byrd, John C, Garcia-Marco, JA, Robak, Tadeusz, Lepretre, S, Furman, RR, Furman, Richard R., Seymour, JF, Jurczak, W, Kay, Neil, O'Brien, Susan, Sohoni, S, Ghia, P, Patel, Priti, Nuri Yenerel, M, Garcia-Marco, Jose A., Byrd, John C., Izumi, Raquel, Kater, Arnon P, Stilgenbauer, S, Izumi, R, Kay, N, Kater, Arnon P., Robak, T, Pinilla-Ibarz, Javier, Lepretre, Stephane, Stilgenbauer, Stephan, Jurczak, Wojciech, Higgins, K, Mato, Anthony, Illés, A, Furman, Richard R, Chanan-Khan, A, Hillmen, Peter, Rothbaum, W, O’Brien, S, Illés, Arpad, Higgins, Kara, Mato, A, Sohoni, Sophia, Yenerel, Mustafa Nuri, Byrd, JC, Kater, AP, Hamdy, A, Garcia-Marco, Jose A, Hamdy, Ahmed, Hillmen, P, Seymour, John F, Ghia, Paolo, Chanan-Khan, Asher, Patel, P   +52 more
core   +1 more source

Acalabrutinib‐related second primary malignancies and nonmelanoma skin cancers in patients with chronic lymphocytic leukaemia (CLL): A systematic review and meta‐analysis of randomised controlled trials (RCTs)

eJHaem, 2021
Acalabrutinib is a second generation Bruton's tyrosine kinase inhibitor and was recently approved in the treatment of chronic lymphocytic leukaemia. We undertook a systematic review and meta‐analysis of randomised controlled trials to determine the risks
Thura W. Htut, Myat M. Han, Kyaw Z. Thein   +2 more
doaj   +1 more source

Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients

Haematologica, 2021
Cardiovascular (CV) toxicities of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib may limit use of this effective therapy in patients with chronic lymphocytic leukemia (CLL).
Jennifer R. Brown, John C. Byrd, Paolo Ghia, Jeff P. Sharman, Peter Hillmen, Deborah M. Stephens, Clare Sun, Wojciech Jurczak, John M. Pagel, Alessandra Ferrajoli, Priti Patel, Lin Tao, Nataliya Kuptsova-Clarkson, Javid Moslehi, Richard R. Furman   +14 more
doaj   +1 more source

FRAILTY ASSESSMENT AS PREDICTOR OF BLEEDING FOR PATIENTS TREATED WITH ACALABRUTINIB

Hematology, Transfusion and Cell Therapy, 2023
Introduction: The American Society of Clinical Oncology (ASCO) promotes the routine use of a comprehensive geriatric assessment, particularly emphasizing frailty, to identify vulnerabilities not detected in the standard clinical evaluation.
TX Carneiro, JLS Sales, JS Tavares, IJM Wanderley, JKD Santos, LBC Leão, LDS Pimentel, NS Moraes   +7 more
doaj   +1 more source

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI

Haematologica, 2018
Ibrutinib and acalabrutinib are irreversible inhibitors of Bruton tyrosine kinase used in the treatment of B-cell malignancies. They bind irreversibly to cysteine 481 of Bruton tyrosine kinase, blocking autophosphorylation on tyrosine 223 and ...
Phillip L.R. Nicolson, Craig E. Hughes, Stephanie Watson, Sophie H. Nock, Alexander T. Hardy, Callum N. Watson, Samantha J. Montague, Hayley Clifford, Aarnoud P. Huissoon, Jean-Daniel Malcor, Mark R. Thomas, Alice Y. Pollitt, Michael G. Tomlinson, Guy Pratt, Steve P. Watson   +14 more
doaj   +1 more source

Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia

Therapeutic Advances in Hematology, 2023
Background: Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) have limited treatment options. Ceralasertib, a selective ataxia telangiectasia and Rad-3-related protein (ATR) inhibitor, demonstrated synergistic preclinical ...
Wojciech Jurczak, Nagah Elmusharaf, Christopher P. Fox, William Townsend, Amanda G. Paulovich, Jeffrey R. Whiteaker, Fanny Krantz, Chuan-Chuan Wun, Graeme Parr, Shringi Sharma, Veerendra Munugalavadla, Richa Manwani, Emma Dean, Talha Munir   +13 more
doaj   +1 more source

Real-World Determinants of Treatment Selection in Frontline Chronic Lymphocytic Leukemia: The FIRST-CLL Study. [PDF]

Hematol Oncol
ABSTRACT Multiple targeted agents are available for first‐line treatment of chronic lymphocytic leukemia (CLL), yet the absence of mature head‐to‐head comparisons makes treatment selection challenging. The prospective, multicenter FIRST‐CLL study evaluated real‐world treatment allocation, and the contribution of biological, clinical, logistical and ...
Perutelli F, Arata M, Pasquale R, Pepe S, Nicolosi M, Deodato M, Piras I, Fioribello E, Bosi A, Moia R, Ferrario A, Schirru M, Boccellato E, Bullo M, Gottardi D, Foglietta M, Galitzia A, Coscia M, Gaidano G, Merli M, Salvetti C, Murru R, Frustaci AM, Freilone R, Olivieri J, Mauro FR, Bruno B, Vitale C.   +27 more
europepmc   +2 more sources

Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data

Cancer Management and Research, 2020
Krista Isaac,1 Anthony R Mato2 1Division of Hematology and Oncology, University of Virginia Health System, Charlottesville, VA, USA; 2Chronic Lymphocytic Leukemia Program, Memorial Sloan Kettering Cancer Center, New York, NY, USACorrespondence: Krista ...
Isaac K, Mato AR
doaj